Immunohistochemistry (PV6000 method) was used to detect the expression of
NF-kappaB/P65 and FHIT in 359 samples of
colorectal carcinoma and 35 samples of normal mucosa at least 5 cm away from the
carcinoma tissues. 198 of the patients were successfully followed up by telephone interview.
RESULTS: The positive expression rates of
NF-kappaB/P65 and FHIT in the
colorectal carcinoma were 67.7% (243/359) and 46.0% (165/359) respectively.
NF-kappaB/P65 and FHIT were all related to the clinical stage, lymphatic invasion, and distant
metastasis (all P < 0.05). The expression of FHIT was negatively correlated with invasion and differentiation degree (r = -0.285 and -0. 254 respectively, both P < 0.05). The 5-year survival rate of the patients with
NF-kappaB/P65 expression was significantly lower than that of the patients negative in the
NF-kappaB/P65 expression while the 5-year survival rate of the patients positive in FHIT expression was significantly higher than those negative in the FHIT expression (X2 = 23.25 and 51.13 respectively, both P < 0. 05).
NF-kappaB/P65 expression in
colorectal carcinoma was negatively correlated with the FHIT expression (r = -0.167, P = 0.019). The expression rate of
NF-kappaB/P65 in
carcinoma was significantly higher, but the expression rate of FHIT in
carcinoma was significantly lower than those in normal mucosa tissues (X2 = 40.78 and 15.93 respectively, both P < 0.05).
NF-kappaB/P65 was an independent prognostic
indicator for disease-free survival and overall survival.
CONCLUSION: